Tim Lugo
Stock Analyst at William Blair
(0.57)
# 4,236
Out of 5,239 analysts
22
Total ratings
38.46%
Success rate
-20.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTGN Vistagen Therapeutics | Downgrades: Market Perform | n/a | $0.62 | - | 4 | Dec 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $52.88 | - | 3 | Oct 30, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $7.91 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $7.72 | +418.13% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $11.05 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $207.86 | - | 2 | Jan 29, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $4.88 | - | 1 | Nov 13, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $42.84 | - | 1 | Sep 21, 2023 | |
| SPRY ARS Pharmaceuticals | Downgrades: Market Perform | n/a | $8.63 | - | 2 | Sep 20, 2023 | |
| AVIR Atea Pharmaceuticals | Initiates: Outperform | n/a | $5.50 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $55.00 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.06 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.87 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $9.20 | +400.00% | 1 | May 30, 2017 |
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.62
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $52.88
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.91
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $7.72
Upside: +418.13%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $11.05
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $207.86
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.88
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $42.84
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.63
Upside: -
Atea Pharmaceuticals
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.50
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $55.00
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $3.06
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.87
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $9.20
Upside: +400.00%